Pfizer’s Chantix Produced More Heart Concerns, FDA Says
This article is for subscribers only.
Pfizer Inc.’s anti-smoking drug Chantix produced a higher rate of heart attacks or strokes in patients using the treatment than those who didn’t take the product, according to an analysis of clinical trials.
The number of cardiovascular issues in patients on Chantix and those who took a placebo was uncommon, the U.S. Food and Drug Administration said today in a safety notice on its website. While the increased risk wasn’t statistically significant for those on Chantix, it seems “more likely that it is related to the drug and not purely a chance finding,” the agency said.